BioCorRx (BICX) Long-Term Deferred Tax (2012 - 2025)

BioCorRx has disclosed Long-Term Deferred Tax across 12 years of filings, most recently posting $13.2 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $13.2 million, up 6.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $13.2 million (up 6.66% YoY), and the FY2025 annual result was $13.2 million, up 6.66% from the prior year.
• Long-Term Deferred Tax came in at $13.2 million for Q4 2025 at BioCorRx, up from $12.3 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $13.2 million in Q4 2025 to a low of $9.4 million in Q4 2021.
• The 3-year median for Long-Term Deferred Tax is $12.3 million (2024), against an average of $11.6 million.
• Across the five-year window, Long-Term Deferred Tax soared 40.7% in 2021 and advanced 6.66% in 2025, its largest moves.
• BioCorRx's Long-Term Deferred Tax stood at $9.4 million in 2021, then soared by 31.86% to $12.3 million in 2024, then gained by 6.66% to $13.2 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $13.2 million (Q4 2025), $12.3 million (Q4 2024), and $9.4 million (Q4 2021), per Business Quant data.